Global Pidotimod Market Insights and Forecast to 2027

Pidomod (CAS 121808-62-6), also known as primo, spectrum leyi, is an immunomodulator, suitable for patients with low immune function of the body, and can be used to prevent acute infection, shorten the course of disease, reduce the severity of the disease, can be used as an auxiliary drug during the acute infection period.Mainly used in children recurrent respiratory tract infection, urinary tract infection (urinary tract infection), chronic bronchitis also has therapeutic effect, to the virus.Influenza and viral herpes are effective.It can also be used for infection caused by pneumococcal pneumonia and escherichia coli, pseudomonas aeruginosa and proteus.

Market Analysis and Insights: Global Pidotimod Market
The global Pidotimod market is valued at US$ XX million in 2019. The market size will reach US$ XX million by the end of 2026, growing at a CAGR of XX% during 2021-2026.

Global Pidotimod Scope and Market Size
Pidotimod market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Pidotimod market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027.

Segment by Type
Piece
Oral Liquid
Capsule
Particles
Other

Segment by Application
Gynecological Infection
Urinary Tract Infection (UTI)
Respiratory Infections
Other

By Company
Active Peptide Company
Reco Tech
Manus Aktteva Biopharma
Joyochem
Changzhou Yinsheng Pharmaceutical
Dr. Reddy’s

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia